Lead Product(s) : Mipomersen
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mipomersen Sodium is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypercholesterolemia.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
November 21, 2011
Lead Product(s) : Mipomersen
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mipomersen
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Ionis Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects
Details : Mipomersen is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
August 11, 2011
Lead Product(s) : Mipomersen
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Ionis Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mipomersen
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Ionis Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mipomersen is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
February 18, 2011
Lead Product(s) : Mipomersen
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Ionis Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mipomersen
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Ionis Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mipomersen is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
May 28, 2010
Lead Product(s) : Mipomersen
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Ionis Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mipomersen
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Ionis Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects
Details : Mipomersen Sodium is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 22, 2010
Lead Product(s) : Mipomersen
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Ionis Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mipomersen
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Ionis Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mipomersen is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
February 03, 2010
Lead Product(s) : Mipomersen
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Ionis Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
